| LBCTR2019040224 | CLCZ696B2319 | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure- PANORAMA | Multicenter, Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LCZ696 Followed by a 52-week Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared With Enalapril in Pediatric Patients From 1 Month to < 18 Years of Age With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction | Interventional | Complete | 07/04/2019 |
| LBCTR2019020192 | CQGE031C2303 | A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in adolescents and adults inadequately controlled with H1-antihistamines | A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in adolescents and adults inadequately controlled with H1-antihistamines | Interventional | Complete | 08/02/2019 |
| LBCTR2020113522 | MERS-201 | Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers | Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers | Interventional | Complete | 28/06/2020 |
| LBCTR2020094573 | CQGE031C2302E1 | CQGE031C2302E1 Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab | A Multi-center, Double-blinded and Open-label Extension Study to Evaluate the Efficacy and Safety of Ligelizumab as Retreatment, Self-administered Therapy and Monotherapy in Chronic Spontaneous Urticaria Patients Who Completed Studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301 | Interventional | Complete | 01/09/2020 |
| LBCTR2019020191 | CAIN457M2302 | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa (SUNRISE) | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa (SUNRISE) | Interventional | Complete | 08/02/2019 |
| LBCTR2019010184 | CLEE011A2404 | COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease | COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease | Interventional | Complete | 11/01/2019 |
| LBCTR2019080232 | CLEE011F2301 | Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer ( MONALEESA 3) | A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment | Interventional | Complete | 06/05/2019 |
| LBCTR2023095432 | PIDMR3 | Evaluation of Pharmacist-Initiated Discharge Medication Reconciliation and Patient Counseling Procedures in the Emergency Department | Evaluation of Pharmacist-Initiated Discharge Medication Reconciliation and Patient Counseling Procedures in the Emergency Department | Interventional | Complete | 08/11/2023 |
| LBCTR2023065377 | N/A | Impact of Health Literacy on Multiple Patient Variables: A Single-Center Observational Study in Lebanon | Impact of Health Literacy on Multiple Patient Variables: A Single-Center Observational Study in Lebanon | Observational | Complete | 14/06/2023 |
| LBCTR2019020194 | CLEE011E2301 | A phase III randomized , double blind, placebo controlled study of LEE011or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI)and goserelin for the treatment of premenopausal women with hormone receptor positive, HER 2 negative, advanced breast cancer. ( MONALEESA 7) | A phase III randomized , double blind, placebo controlled study of LEE011or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI)and goserelin for the treatment of premenopausal women with hormone receptor positive, HER 2 negative, advanced breast cancer. | Interventional | Complete | 15/02/2019 |